despit
advanc
knowledg
etiolog
treatment
manag
communityacquir
pneumonia
cap
remain
major
caus
morbid
mortal
worldwid
although
wide
varieti
etiolog
agent
caus
cap
limit
number
agent
respons
vast
major
case
tabl
role
microbiolog
test
patient
cap
still
matter
debat
unfortun
specif
etiolog
agent
determin
approxim
half
cap
case
even
best
avail
diagnost
method
use
convent
laboratori
test
capcaus
pathogen
poor
current
clinic
practic
guidelin
recommend
test
sever
affect
individu
nucleic
method
potenti
improv
timeli
sensit
accuraci
test
use
detect
respiratori
pathogen
advanc
realtim
amplif
system
multiplex
analysi
liquidbead
array
key
develop
individualpathogen
multipathogen
panel
approach
diagnosi
cap
streptococcu
pneumonia
account
approxim
twothird
case
cap
etiolog
determin
earli
accur
diagnosi
pneumococc
pneumonia
problemat
limit
convent
method
sputum
blood
cultur
slow
lack
sensit
particularli
patient
receiv
previou
antibiot
treatment
falseposit
sputum
cultur
result
may
occur
result
oropharyng
contamin
gram
stain
sputum
specimen
frequent
unreli
pneumococc
urinari
antigen
test
offer
promis
increas
sensit
report
variabl
specif
depend
compar
chosen
way
test
perform
interpret
popul
studi
number
investig
develop
pcrbase
assay
detect
pneumonia
respiratori
tract
sampl
vari
degre
success
major
concern
pcrbase
assay
applic
presenc
target
gene
close
relat
viridan
group
streptococci
asymptomat
colon
pneumonia
varieti
pneumococc
gene
target
includ
lyta
pli
psaa
fragment
use
pcr
assay
clear
pli
found
exclus
pneumonia
use
realtim
pcr
method
address
second
concern
realtim
pcr
amount
target
nucleic
acid
sampl
invers
relat
cycl
threshold
c
valu
relationship
use
establish
c
valu
cutoff
provid
optim
sensit
specif
prevent
falseposit
result
due
colon
small
number
pneumococci
yang
et
al
report
sensit
specif
quantit
realtim
pcr
assay
pli
composit
refer
standard
compris
gram
stain
sputum
specimen
sputum
blood
c
valu
use
cutoff
presenc
pli
gene
close
relat
viridan
group
streptococci
may
explain
rel
poor
specif
assay
panel
realtim
pcr
assay
target
lyta
gene
pneumonia
mip
gene
legionella
pneumophila
rrna
gene
haemophilu
influenza
streptococcu
pyogen
mycoplasma
pneumonia
chlamydophilia
pneumonia
use
morozumi
et
al
analyz
clinic
sampl
children
adult
pneumonia
analysi
time
h
analyt
sensit
rang
copiesreact
depend
pathogen
sensit
specif
rel
convent
cultur
clinic
specimen
follow
pneumonia
h
influenza
pyogen
pneumonia
respect
cultur
c
pneumonia
perform
posit
pcr
result
obtain
patient
serolog
evid
infect
patient
result
posit
legionella
speci
cultur
pcr
addit
found
excel
correl
semiquantit
cultur
result
c
valu
pcr
assay
pneumonia
h
influenza
clinic
specimen
patient
posit
pcr
neg
cultur
result
pathogen
histori
previou
antibiot
therapi
commerci
multiplex
assay
use
microwel
hybrid
detect
bordetella
pertussi
l
pneumophila
legionella
micdadei
pneumonia
c
pneumonia
pneumoplex
prodess
l
pneumophila
pneumonia
c
pneumonia
chamyleg
argen
technolog
cumbersom
realtim
method
separ
amplif
detect
step
longer
time
need
complet
analysi
neither
assay
valid
larg
number
clinic
specimen
clear
us
food
drug
administr
fda
diagnost
use
molecular
diagnost
hold
much
promis
detect
common
atyp
bacteri
pathogen
caus
cap
analysi
complet
hour
rather
day
detect
typic
pathogen
week
detect
atyp
pathogen
approach
elimin
concern
decreas
organ
viabil
associ
transport
specimen
effect
previou
antibiot
therapi
realtim
pcr
panel
includ
common
caus
pathogen
cap
could
substanti
increas
diagnost
yield
clinic
practic
unfortun
assay
standard
wide
avail
except
l
pneumophila
mycobacterium
tuberculosi
tabl
fdaclear
nucleic
assay
bacteri
respiratori
pathogen
avail
one
major
limit
molecular
diagnost
approach
detect
bacteri
caus
pneumonia
cultur
would
still
requir
obtain
isol
antimicrobialsuscept
test
near
futur
method
supplement
rather
replac
culturebas
method
pathogen
antibiot
resist
concern
current
known
respiratori
virus
accur
data
mani
cap
case
caus
viral
pathogen
lack
sever
acut
respiratori
syndrom
coronaviru
strain
influenza
viru
recent
adenoviru
serotyp
focus
attent
virus
caus
sever
lower
respiratori
tract
infect
histor
clinic
virolog
laboratori
use
cell
cultur
immunoassay
detect
usual
suspect
influenza
virus
b
parainfluenza
virus
respiratori
syncyti
viru
adenoviru
recent
nucleic
method
use
detect
respiratori
virus
often
dramat
increas
sensit
howev
divers
complex
viral
flora
present
signific
challeng
nucleic
detect
system
discoveri
new
respiratori
virus
sinc
metapneumoviru
sever
acut
respiratori
syndrom
coronaviru
influenza
viru
strain
coronaviru
strain
human
present
new
challeng
comprehens
viral
diagnost
multiplex
pcr
microarraybas
system
provid
potenti
solut
complex
diagnost
problem
howev
number
virus
detect
singl
multiplex
pcr
rel
small
although
microarray
detect
mani
pathogen
approach
impract
routin
diagnost
use
recent
differ
highli
multiplex
pcr
assay
respiratori
virus
use
microspher
flow
cytometri
luminex
xmap
technolog
decod
pcr
product
commerci
develop
eragen
bioscienc
genacoqiagen
luminextm
bioscienc
one
assay
luminextm
bioscienc
recent
clear
fda
diagnost
use
assay
detect
differ
respiratori
virus
singl
pcr
analysi
time
h
genacoqiagen
product
uniqu
provid
separ
rna
dna
target
panel
rna
panel
detect
respiratori
virus
wherea
dna
panel
detect
bacteri
pathogen
includ
pneumonia
l
pneumophila
c
pneumonia
neisseria
meningitidi
pneumonia
h
influenza
acinteobact
baumannii
adenoviru
serotyp
assay
provid
high
throughput
much
less
labor
intens
costeffect
perform
similar
number
singletarget
assay
parallel
test
sensit
specif
compar
better
culturebas
method
depend
target
similar
singletarget
pcr
individu
panel
target
real
valu
system
expand
capabl
diagnost
laboratori
detect
virus
commonli
sought
rhinovirus
coronavirus
metapneumoviru
littl
effort
current
expend
detect
usual
suspect
expand
panel
also
detect
mix
viral
infect
mix
infect
bacteria
virus
increas
diagnost
yield
respiratori
pathogen
could
translat
better
manag
lower
respiratori
tract
infect
howev
studi
address
impact
molecular
diagnost
manag
pneumonia
oosterheert
et
al
conduct
random
control
trial
involv
adult
lower
respiratori
tract
infect
dutch
hospit
patient
respiratori
tract
sampl
test
realtim
pcr
method
common
respiratori
virus
atyp
pathogen
result
patient
intervent
group
report
attend
physician
respiratori
tract
sampl
control
group
also
test
use
standard
microbiolog
method
author
found
realtim
pcr
method
significantli
increas
diagnost
yield
compar
standard
diagnost
test
alon
reduc
antibiot
use
durat
hospit
stay
treatment
cost
studi
larger
number
patient
differ
set
need
done
better
understand
impact
method
patient
care
molecular
method
detect
respiratori
pathogen
dramat
increas
diagnost
yield
consequ
better
identifi
patient
would
benefit
antibiot
therapi
clinic
trial
unfortun
method
standard
fdaclear
diagnost
test
respiratori
pathogen
tabl
debat
role
microbiolog
test
diagnosi
cap
expens
associ
clinic
trial
serv
discourag
diagnost
industri
develop
new
diagnost
test
cap
partnership
diagnost
pharmaceut
compani
develop
companion
diagnost
along
new
drug
cap
could
potenti
benefit
clinic
trial
ultim
provid
clinic
laboratori
valid
test
could
better
assist
clinician
care
individu
patient
pneumonia
